Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R9KG
|
|||
| Former ID |
DIB015327
|
|||
| Drug Name |
Temanogrel
|
|||
| Synonyms |
Temanogrel hydrochloride; APD-791; 5-HT 2a inverse agonist (arterial thrombosis), Arena Pharmaceutical
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 1 | [1] | |
| Company |
Arena Pharmaceuticals; Arena Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H28N4O4
|
|||
| Canonical SMILES |
CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)OC)OCCN4CCOCC4
|
|||
| InChI |
1S/C24H28N4O4/c1-27-22(8-9-25-27)21-17-19(26-24(29)18-4-3-5-20(16-18)30-2)6-7-23(21)32-15-12-28-10-13-31-14-11-28/h3-9,16-17H,10-15H2,1-2H3,(H,26,29)
|
|||
| InChIKey |
ZEOQUKRCASTCFR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 887936-68-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Agonist | [2], [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02034292) Safety Study of APD-791 With Aspirin and/or Clopidogrel. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Arena Pharmaceuticals. | |||
| REF 3 | Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.